Literature DB >> 12578848

Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans.

E Sally Ward1, Jinchun Zhou, Victor Ghetie, Raimund J Ober.   

Abstract

IgG is the most abundant serum antibody and is an essential component of the humoral immune response. It is known that the 'neonatal' Fc receptor (FcRn) plays a role in maintaining constant serum IgG levels by acting as a protective receptor which binds and salvages IgG from degradation. However, the cellular mechanism that is involved in serum IgG homeostasis is poorly understood. In the current study we address this issue by analyzing the intracellular fate in human endothelial cells of IgG molecules which bind with different affinities to FcRn. The studies show that IgG which do not bind to FcRn accumulate in the lysosomal pathway, providing a cellular explanation for short serum persistence of such antibodies. We have also investigated the saturability of the homeostatic system and find that it has limited capacity. Our observations have direct relevance to the understanding and treatment of IgG deficiency, and to the effective application of therapeutic antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578848     DOI: 10.1093/intimm/dxg018

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  64 in total

1.  Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fcgamma-receptor.

Authors:  Steven M Claypool; Bonny L Dickinson; Jessica S Wagner; Finn-Eirik Johansen; Nanda Venu; Jason A Borawski; Wayne I Lencer; Richard S Blumberg
Journal:  Mol Biol Cell       Date:  2004-02-06       Impact factor: 4.138

2.  Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level.

Authors:  Raimund J Ober; Cruz Martinez; Xuming Lai; Jinchun Zhou; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

Review 3.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

4.  Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.

Authors:  Carlos Vaccaro; Roger Bawdon; Sylvia Wanjie; Raimund J Ober; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

5.  Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model.

Authors:  Jonghan Kim; William L Hayton; John M Robinson; Clark L Anderson
Journal:  Clin Immunol       Date:  2006-10-13       Impact factor: 3.969

6.  The chicken yolk sac IgY receptor, a mammalian mannose receptor family member, transcytoses IgY across polarized epithelial cells.

Authors:  Devin B Tesar; Evelyn J Cheung; Pamela J Bjorkman
Journal:  Mol Biol Cell       Date:  2008-02-06       Impact factor: 4.138

7.  Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.

Authors:  Frank A Engler; Bo Zheng; Joseph P Balthasar
Journal:  Pharm Res       Date:  2013-11-08       Impact factor: 4.200

Review 8.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

9.  Expression of neonatal Fc receptor in the eye.

Authors:  Michael B Powner; Jenny A G McKenzie; Gregory J Christianson; Derry C Roopenian; Marcus Fruttiger
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-19       Impact factor: 4.799

10.  Uptake and intra-inclusion accumulation of exogenous immunoglobulin by Chlamydia-infected cells.

Authors:  David V Pollack; Nancy L Croteau; Elizabeth S Stuart
Journal:  BMC Microbiol       Date:  2008-12-05       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.